**AIVC recommendations for the composition of influenza vaccine for Australia in 2019**

15 October 2018

The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on Wednesday 10th October 2018, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2019. During this meeting, the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2017-2018 vaccines, and the availability of candidate vaccines viruses and reagents.

The committee recommended that the following viruses be used for influenza vaccines in the 2019 southern hemisphere influenza season:

**Egg based Quadrivalent influenza vaccine:**

* an A/Michigan/45/2015 (H1N1)pdm09-like virus;
* an A/Switzerland/8060/2017 (H3N2)-like virus;
* a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
* a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).

**Egg based Trivalent vaccines:**

* an A/Michigan/45/2015 (H1N1)pdm09-like virus;
* an A/Switzerland/8060/2017 (H3N2)-like virus; and
* a B/Phuket/3073/2013-like (B/Yamagata/16/88 lineage)

**AIVC recommendations for the composition of influenza vaccine for Australia in 2018**

18 October 2017

The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on 11th October 2017, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2018. During this meeting, the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2016-2017 vaccines, and the availability of candidate vaccines viruses and reagents.

* The committee recommended that the TGA should adopt the following WHO recommendation issued on 28 September 2017, for the 2018 Southern Hemisphere influenza vaccines the trivalent influenza vaccine components for the Australian 2018 influenza season should contain the following:
  + **A (H1N1):** an A/Michigan/45/2015 (H1N1)pdm09-like virus
  + **A (H3N2):** an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus
  + **B:** a B/Phuket/3073/2013-like virus.
* the quadrivalent influenza vaccine for the Australian 2018 influenza season should contain the trivalent influenza vaccine components listed above, and the additional B strain:
  + **B:**a B/Brisbane/60/2008-like virus.

**AIVC recommendations for the composition of influenza vaccine for Australia in 2017**

25 October 2016

The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on 13th October 2016, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2017. During this meeting, the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2015-2016 vaccines, and the availability of candidate vaccines viruses and reagents.

The committee recommended that the TGA should adopt the September 2016 WHO recommendations;

* the trivalent influenza vaccine components for the Australian 2017 influenza season should contain the following:
  + **A (H1N1)**: an A/Michigan/45/2015 (H1N1)pdm09 like virus
  + **A (H3N2)**: an A/Hong Kong/4801/2014 (H3N2) like virus
  + **B**: a B/Brisbane/60/2008 like virus
* the quadrivalent influenza vaccine for the Australian 2017 influenza season should contain the trivalent influenza vaccine components listed above, and the additional B strain:
  + B: a B/Phuket/3073/2013 like virus.

**AIVC recommendations for the composition of influenza vaccine for Australia in 2016**

**Australian Influenza Vaccine Committee**

15 October 2015

The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on 8th October 2015, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2016. During this meeting, the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2014-2015 vaccines, and the availability of candidate vaccines viruses and reagents.

The committee recommended that the TGA should adopt the September 2015 WHO recommendations;

* the trivalent influenza vaccine components for the Australian 2016 influenza season should contain the following:
  + **A (H1N1)**: an A/California/7/2009 (H1N1)pdm09 like virus
  + **A (H3N2)**: an A/Hong Kong/4801/2014 (H3N2) like virus
  + **B**: a B/Brisbane/60/2008 like virus
* the quadrivalent influenza vaccine for the Australian 2016 influenza season should contain the trivalent influenza vaccine components listed above, and the additional B strain:
  + B/Phuket/3073/2013 like virus.

**AIVC recommendations for the composition of influenza vaccine for Australia in 2015**

**Australian Influenza Vaccine Committee**

14 October 2014

The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on 9 October 2014, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2015. During this meeting, the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2013-2014 vaccines, and the availability of candidate vaccines viruses and reagents. The committee recommended that the TGA should adopt the September WHO recommendations; the trivalent influenza vaccine components for the Australian 2015 influenza season should contain the following:

* **A (H1N1):** an A/California/7/2009 (H1N1) - like virus, 15 µg HA per dose
* **A (H3N2):** an A/Switzerland/9715293/2013 (H3N2) - like virus, 15 µg HA per dose
* **B:** a B/Phuket/3073/2013 - like virus, 15 µg HA per dose

Quadrivalent vaccines should contain viruses listed above, plus the additional B virus:

* B/Brisbane/60/2008-like virus, 15 µg HA per dose.

**AIVC recommendations for the composition of influenza vaccine for Australia in 2014**

**Australian Influenza Vaccine Committee**

7 November 2013

The Australian Influenza Vaccine Committee (AIVC) met at TGA, Canberra, on 10 October 2013, to recommend influenza viruses to be used in the composition of the influenza vaccines for 2014. During this meeting, the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2012-2013 vaccines, and the availability of candidate vaccines viruses and reagents. The committee recommended that the TGA should adopt the September WHO recommendations; the trivalent influenza vaccine components for the Australian 2014 influenza season should contain the following:

* **A (H1N1):** an A/California/7/2009 (H1N1) - like virus, 15 µg HA per dose
* **A (H3N2):** an A/Texas/50/2012 (H3N2) - like virus\*, 15 µg HA per dose
* **B:**a B/Massachusetts/2/2012 - like virus, 15 µg HA per dose

Quadrivalent vaccines should contain viruses listed above, plus the additional B virus:

* B/Brisbane/60/2008-like virus, 15 µg HA per dose.

Composition of Australian Influenza Vaccine for the 2013 season

This page contains information on the recommended influenza vaccine for the Southern Hemisphere winter 2013.

 Page last updated: 13 November 2012

The Australian Influenza Vaccine Committee (AIVC) met on 3 October 2012, and agreed to adopt the [September WHO recommendations](http://www.who.int/influenza/vaccines/virus/recommendations/2013_south/en/index.html).  
  
The Committee decided that the influenza vaccine components for the 2013 season should contain the following:

* A (H1N1): an A/California/7/2009 (H1N1) - like virus, 15 µg HA per dose
* A (H3N2): an A/Victoria/361/2011 (H3N2) - like virus, 15 µg HA per dose
* B: a B/Wisconsin/1/2010 - like virus, 15 µg HA per dose

**Seasonal influenza vaccines 2012**

**Related information**

* [2012 seasonal influenza vaccines for use in children](https://www.tga.gov.au/alert/seasonal-flu-vaccine-2012-seasonal-influenza-vaccines-use-children)  
  6 February 2012

6 February 2012

Influenza vaccines can change from year to year as new strains of influenza virus appear. There has been no evidence of the emergence of a new strain and, therefore, the Australian Influenza Vaccine Committee (AIVC) has recommended no change to the composition of influenza vaccines for Australia from 2011 to 2012.

For the 2012 influenza season, the TGA has registered 6 vaccines for use in the following age groups:

<https://surv.esr.cri.nz/PDF_surveillance/Virology/FluVac/FluVac2011.pdf>

The Australian Influenza Vaccine Committee met with New Zealand representatives (Appendix 1) on 6 October 2010 to consult on the seasonal influenza vaccine composition for New Zealand, Australia and South Africa for 2011. The recommended composition (Table 1) was: • A(H1N1) an A/California/7/2009 (H1N1) - like virus\* • A(H3N2) an A/Perth/16/2009 (H3N2) - like virus • B a B/Brisbane/60/2008 - like virus \* Note: A/California/7/2009 is a pandemic A(H1N1) virus, also known as pandemic (H1N1) 09

<https://www.who.int/influenza/vaccines/200902_recommendation.pdf>